Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00297089 | A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | PHASE1 | COMPLETED | 165 | — | — | Nov 1, 2006 | Jan 1, 2009 | Jan 31, 2013 | 48 | United States, Czechia +4 |
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | Pemetrexed + ABT-751 |
| B | PLACEBO_COMPARATOR | Pemetrexed + placebo |
| Name | Type | Description |
|---|---|---|
| ABT-751 | DRUG | 200 mg ABT-751 daily for 14 days every 21 days |
| pemetrexed | DRUG | Standard pemetrexed every 21 days |
| placebo | DRUG | Placebo daily for 14 days every 21 days |
Inclusion Criteria: * Pathologically documented NSCLC * Locally advanced (Stage III) or metastatic (Stage IV) NSCLC * Only one prior anti-tumor treatment regimen in the non-curative setting (i.e., 2nd-line therapy) * Only one prior anti-tumor treatment regimen in the curative setting * Progressive ...